Ilana Schlam
Breast Medical Oncologist Dana-Farber Cancer Institute
Seminars
Wednesday 7th October 2026
Potential Applications of MRD Testing in Early Stage Breast Cancer
4:10 pm
- Understand the main approaches to ctDNA testing and their limitations in detecting minimal residual disease
- Review how ctDNA detection and changes during neoadjuvant treatment relate to recurrence risk
- Discuss the evidence for ctDNA surveillance after treatment and ongoing trials testing if results can guide therapy
